| Dr Andrew Christopher Wiechert, MD | |
|
75 Francis St, Asb1-3-078, Boston, MA 02115-6110 | |
| (617) 732-7801 | |
| Not Available |
| Full Name | Dr Andrew Christopher Wiechert |
|---|---|
| Gender | Male |
| Speciality | Obstetrics/gynecology |
| Experience | 14 Years |
| Location | 75 Francis St, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235455684 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beth Israel Deaconess Medical Center | Boston, MA | Hospital |
| Winchester Hospital | Winchester, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc | 4486567104 | 1344 |
News Archive
Ipsen a global biopharmaceutical group, today announced that its partner Roche disclosed results of five Phase III 24-week studies for taspoglutide for type 2 diabetes at the American Diabetes Association's (ADA) 70th Annual Scientific Sessions. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen's research is developed by Roche. This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation.
A team of researchers at the MedUni Vienna's Institute of Medical Genetics has discovered that two genes (TSC/Tuberin and PRAS40) are extremely important regulators in the development of stem cells: if these genes are switched off, the stem cells do not develop but instead die a programmed cell death.
Cellectis bioresearch, the specialist in genome customization and subsidiary of Cellectis and Helix BioService & Consultants Pvt Ltd (Helix Biocon), today announced that they will join forces for the promotion of Cellectis bioresearch's meganuclease-based products and services in India.
Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system ("CNS"), including fibromyalgia syndrome ("FM") and post-traumatic stress disorder ("PTSD"), has announced the effectiveness of a company name change to Tonix Pharmaceuticals Holding Corp. and the commencement of trading under the stock symbol "TNXP".
At the beginning of September, Mellow Hope completed the clinical trial of Influenza A (H1N1) Vaccine (Split Virion). The company received the clinical approval from the State Food and Drug Administration (SFDA) http://eng.sfda.gov.cn/eng. Production will be started shortly.
› Verified 3 days ago
| Entity Name | Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1518908136 PECOS PAC ID: 4486567104 Enrollment ID: O20031204000710 |
News Archive
Ipsen a global biopharmaceutical group, today announced that its partner Roche disclosed results of five Phase III 24-week studies for taspoglutide for type 2 diabetes at the American Diabetes Association's (ADA) 70th Annual Scientific Sessions. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen's research is developed by Roche. This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation.
A team of researchers at the MedUni Vienna's Institute of Medical Genetics has discovered that two genes (TSC/Tuberin and PRAS40) are extremely important regulators in the development of stem cells: if these genes are switched off, the stem cells do not develop but instead die a programmed cell death.
Cellectis bioresearch, the specialist in genome customization and subsidiary of Cellectis and Helix BioService & Consultants Pvt Ltd (Helix Biocon), today announced that they will join forces for the promotion of Cellectis bioresearch's meganuclease-based products and services in India.
Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system ("CNS"), including fibromyalgia syndrome ("FM") and post-traumatic stress disorder ("PTSD"), has announced the effectiveness of a company name change to Tonix Pharmaceuticals Holding Corp. and the commencement of trading under the stock symbol "TNXP".
At the beginning of September, Mellow Hope completed the clinical trial of Influenza A (H1N1) Vaccine (Split Virion). The company received the clinical approval from the State Food and Drug Administration (SFDA) http://eng.sfda.gov.cn/eng. Production will be started shortly.
› Verified 3 days ago
| Entity Name | Lahey Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063447316 PECOS PAC ID: 2264336528 Enrollment ID: O20040629001269 |
News Archive
Ipsen a global biopharmaceutical group, today announced that its partner Roche disclosed results of five Phase III 24-week studies for taspoglutide for type 2 diabetes at the American Diabetes Association's (ADA) 70th Annual Scientific Sessions. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen's research is developed by Roche. This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation.
A team of researchers at the MedUni Vienna's Institute of Medical Genetics has discovered that two genes (TSC/Tuberin and PRAS40) are extremely important regulators in the development of stem cells: if these genes are switched off, the stem cells do not develop but instead die a programmed cell death.
Cellectis bioresearch, the specialist in genome customization and subsidiary of Cellectis and Helix BioService & Consultants Pvt Ltd (Helix Biocon), today announced that they will join forces for the promotion of Cellectis bioresearch's meganuclease-based products and services in India.
Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system ("CNS"), including fibromyalgia syndrome ("FM") and post-traumatic stress disorder ("PTSD"), has announced the effectiveness of a company name change to Tonix Pharmaceuticals Holding Corp. and the commencement of trading under the stock symbol "TNXP".
At the beginning of September, Mellow Hope completed the clinical trial of Influenza A (H1N1) Vaccine (Split Virion). The company received the clinical approval from the State Food and Drug Administration (SFDA) http://eng.sfda.gov.cn/eng. Production will be started shortly.
› Verified 3 days ago
| Entity Name | Winchester Physician Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184606865 PECOS PAC ID: 4486540994 Enrollment ID: O20060215000452 |
News Archive
Ipsen a global biopharmaceutical group, today announced that its partner Roche disclosed results of five Phase III 24-week studies for taspoglutide for type 2 diabetes at the American Diabetes Association's (ADA) 70th Annual Scientific Sessions. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen's research is developed by Roche. This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation.
A team of researchers at the MedUni Vienna's Institute of Medical Genetics has discovered that two genes (TSC/Tuberin and PRAS40) are extremely important regulators in the development of stem cells: if these genes are switched off, the stem cells do not develop but instead die a programmed cell death.
Cellectis bioresearch, the specialist in genome customization and subsidiary of Cellectis and Helix BioService & Consultants Pvt Ltd (Helix Biocon), today announced that they will join forces for the promotion of Cellectis bioresearch's meganuclease-based products and services in India.
Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system ("CNS"), including fibromyalgia syndrome ("FM") and post-traumatic stress disorder ("PTSD"), has announced the effectiveness of a company name change to Tonix Pharmaceuticals Holding Corp. and the commencement of trading under the stock symbol "TNXP".
At the beginning of September, Mellow Hope completed the clinical trial of Influenza A (H1N1) Vaccine (Split Virion). The company received the clinical approval from the State Food and Drug Administration (SFDA) http://eng.sfda.gov.cn/eng. Production will be started shortly.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Andrew Christopher Wiechert, MD Lahey Hospital And Medical Center, 41 Mall Road, Burlington, MA 01805-0001 Ph: (781) 744-8560 | Dr Andrew Christopher Wiechert, MD 75 Francis St, Asb1-3-078, Boston, MA 02115-6110 Ph: (617) 732-7801 |
News Archive
Ipsen a global biopharmaceutical group, today announced that its partner Roche disclosed results of five Phase III 24-week studies for taspoglutide for type 2 diabetes at the American Diabetes Association's (ADA) 70th Annual Scientific Sessions. Taspoglutide, the first once weekly glucagon-like peptide-1 (GLP-1) analogue based on a human sequence, originating from Ipsen's research is developed by Roche. This compound is similar to the natural hormone GLP-1 which has a key role in blood sugar regulation.
A team of researchers at the MedUni Vienna's Institute of Medical Genetics has discovered that two genes (TSC/Tuberin and PRAS40) are extremely important regulators in the development of stem cells: if these genes are switched off, the stem cells do not develop but instead die a programmed cell death.
Cellectis bioresearch, the specialist in genome customization and subsidiary of Cellectis and Helix BioService & Consultants Pvt Ltd (Helix Biocon), today announced that they will join forces for the promotion of Cellectis bioresearch's meganuclease-based products and services in India.
Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system ("CNS"), including fibromyalgia syndrome ("FM") and post-traumatic stress disorder ("PTSD"), has announced the effectiveness of a company name change to Tonix Pharmaceuticals Holding Corp. and the commencement of trading under the stock symbol "TNXP".
At the beginning of September, Mellow Hope completed the clinical trial of Influenza A (H1N1) Vaccine (Split Virion). The company received the clinical approval from the State Food and Drug Administration (SFDA) http://eng.sfda.gov.cn/eng. Production will be started shortly.
› Verified 3 days ago
Sheela S Maru, MD Obstetrics & Gynecology Medicare: Medicare Enrolled Practice Location: 850 Harrison Ave, Yacc 4, Boston, MA 02118 Phone: 617-414-2000 Fax: 617-414-5798 | |
Dr. Devon Abt Harris, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 330 Brookline Ave # Shapiro8, Boston, MA 02215 Phone: 617-667-3736 Fax: 617-667-7493 | |
Maureen E Paul, M.D. Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 1055 Commonwealth Ave, Boston, MA 02215 Phone: 917-208-9521 | |
Charles-chidi W Obasiolu, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: Ctr For Fertility & Repro Hlth, 133 Brookline Ave, Boston, MA 02215 Phone: 617-421-2987 Fax: 617-421-2989 | |
Dr. Erik M Clinton, M.D. Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 750 Washington St, Boston, MA 02111 Phone: 617-636-5000 | |
Evelyn Hall, MD Obstetrics & Gynecology Medicare: Accepting Medicare Assignments Practice Location: 800 Washington St, Boston, MA 02111 Phone: 269-552-8685 | |
Toni Beth Walzer, MD Obstetrics & Gynecology Medicare: Not Enrolled in Medicare Practice Location: 333 Longwood Avenue, Adolescent Gynecology, Boston, MA 02115 Phone: 617-355-5785 |